OBJECTIVES Retinal vein occlusion (RVO) is associated with an increased risk of future cardiovascular events. Statin therapy is a key cornerstone in prevention for patients at high cardiovascular risk. However, little is known about the role of statin therapy for patients with RVO. This study evaluated whether statin treatment in patients with RVO was associated with a lower risk of cardiovascular events.
METHODS
A population-based, nested case-control study was conducted with a cohort of newly diagnosed RVO patients without prior cardiovascular disease between 2008 and 2020 using a nationwide health claims database in Korea. From this cohort of RVO patients, we identified cases of cardiovascular events (stroke or myocardial infarction) after RVO and matched controls based on sex, age, insurance type, antiplatelet use, and underlying comorbidities using 1:2 incidence density sampling.
RESULTS
Using a cohort of 142,759 patients with newly diagnosed RVO, we selected 6,810 cases and 13,620 matched controls. A significantly lower risk of cardiovascular events (adjusted odds ratio, 0.604; 95% confidence interval, 0.557 to 0.655) was observed in RVO patients with statin treatment than in those without statin treatment. Statin treatment was associated with a reduced risk for both stroke and myocardial infarction after RVO. Longer statin treatment after RVO was associated with a lower risk for cardiovascular events.
CONCLUSIONS
Statin treatment was associated with a lower risk for future cardiovascular events in patients with newly diagnosed RVO. Further studies are warranted to clarify the potential cardiovascular preventive role of statins in patients with RVO.
Summary
Korean summary
· 망막정맥폐색 환자들은 심뇌혈관질환의 발생 위험이 높다고 알려져 있다.
· 이번 연구를 통해 망막정맥폐색의 발생 이후 스타틴을 복용한 환자들에서 심근경색 및 뇌졸중 발생 위험도가 감소함을 확인하였다.
· 고위험군인 망막정맥폐색 환자들에서 적극적인 스타틴의 사용이 심뇌혈관질환의 예방에 도움이 될 수 있을 것이다.
Key Message
· Statin was associated with a lower risk of cardiovascular events in RVO patients.
· The reduced risk was observed in both stroke and myocardial infarction after RVO.
· Statins might be a good candidate for cardiovascular prevention in RVO patients.
Citations
Citations to this article as recorded by
Oclusión venosa de retina y su asociación con la enfermedad vascular aterosclerótica María Larrousse Morellón, Yéssica López Loureiro, Susana Ruiz Bilbao Medicina Clínica.2024; 163(4): 199. CrossRef
Zerumbone Inhibits the Viability, Motility, and Angiogenesis of Human Retinal Microvascular Endothelial Cells (HRCECs) by Inhibiting Vascular Endothelial Growth Factor Jiexin Yu, Shule Jiang, Yanli Liu Current Eye Research.2024; 49(11): 1201. CrossRef
Retinal venous occlusion and its association with atherosclerotic vascular disease María Larrousse Morellón, Yéssica López Loureiro, Susana Ruiz Bilbao Medicina Clínica (English Edition).2024; 163(4): 199. CrossRef
Retinal Findings and Cardiovascular Risk: Prognostic Conditions, Novel Biomarkers, and Emerging Image Analysis Techniques Joseph Colcombe, Rusdeep Mundae, Alexis Kaiser, Jacques Bijon, Yasha Modi Journal of Personalized Medicine.2023; 13(11): 1564. CrossRef